Clincosm LogoSign in Get a demo

Establishing a Dose-response Relationship With Accelerated Transcranial Magnetic Stimulation

Sponsor
Stanford University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04243798
Collaborator
(none)
100
Enrollment
1
Location
2
Arms
65.5
Anticipated Duration (Months)
1.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. In a double-blind, randomized, sham-controlled fashion, half the participants will receive accelerated theta-burst stimulation while half will receive sham treatment.

Condition or Disease Intervention/Treatment Phase
  • Device: Active TBS-DLPFC
  • Device: Sham TBS-DLPFC
 N/A

Detailed Description

Repetitive transcranial magnetic stimulation (rTMS) is an established therapy for treatment-resistant depression. The approved method for treatment is 10Hz stimulation for 40 min over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been effective in real world situations. The limitations of this approach include the duration of the treatment (approximately 40 minutes per treatment session, 5 days per week, for 4-8 weeks). Recently, we have pursued modifying the treatment parameters to reduce treatment times with an accelerated treatment paradigm with great preliminary success. This study aims to further study our accelerated protocol and examine changes in neuroimaging biomarkers.

Dr. Nolan Williams is the Principle Investigator on the grant associated for this study and so is listed as Study Director on the study record.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Utilizing Changes in Human Brain Connectivity to Establish a Dose-response Relationship Involved in the Therapeutic Actions of Prefrontal Brain Stimulation on Depression Symptoms
Actual Study Start Date :
Jun 15, 2021
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
Dec 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active TBS-DLPFC

The active group will receive theta-burst TMS stimulation.

Device: Active TBS-DLPFC
Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004). Stimulation will be delivered to the L-DLPFC using a MagPro x100 TMS system (MagVenture, Denmark).
Sham Comparator: Sham TBS-DLPFC

The sham group will receive sham theta-burst TMS stimulation.

Device: Sham TBS-DLPFC
The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.

Outcome Measures

Primary Outcome Measures

  1. Change in resting state functional connectivity of the subgenual anterior cingulate cortex (sgACC) and the default mode network (DMN). [At baseline (day 3) and at immediate post-treatment follow up visit (day 8).]

    Assessment of functional connectivity of sgACC to the DMN using magnetic resonance imaging.

Secondary Outcome Measures

  1. Relationship between clinical improvement and resting state functional connectivity between the sgACC and DMN in active vs. sham participants. [At baseline (day 3) and at immediate post-treatment follow up visit (day 8).]

    Assessment of clinical improvement by the Montgomery Asberg Depression Rating Scale-self report (MADRS-S). The 9-item self-report version of the MADRS has an overall score range from 0-27, with higher scores corresponding to higher levels of depression. Assessment of functional connectivity of sgACC to the DMN using magnetic resonance imaging.

  2. Relationship between acute mood state and resting state functional connectivity between the sgACC and DMN in active vs. sham participants. [At baseline (day 3) and at immediate post-treatment follow up visit (day 8).]

    Assessment of acute mood state by the Immediate Mood Scaler-12 item (IMS-12). Assessment of functional connectivity of sgACC to the DMN using magnetic resonance imaging.

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Male or Female, between the ages of 22 and 65 at the time of screening.

  2. Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during fMRI assessments and aiTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.

  3. Currently diagnosed with Major Depressive Disorder (MDD) and meets criteria for a Major Depressive Episode, according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5).

  4. Medical records confirming a history of moderate to severe treatment-resistance as defined by a score of 7-14 on the Maudsley Staging Method (MSM3).

  5. MADRS score of ≥20 at screening (Visit 1).

  6. TMS naive.

  7. Access to ongoing psychiatric care before and after completion of the study.

  8. Access to clinical rTMS after study completion.

  9. Must be on a stable antidepressant therapeutic regimen for 6 weeks prior to study enrollment and agree to continue this regimen throughout the study period.

  10. In good general health, as evidenced by medical history.

  11. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.

  12. Agreement to adhere to Lifestyle Considerations throughout study duration.

Lifestyle considerations:

  1. Abstain from becoming pregnant from the screening visit (Visit 1) until after the final study visit (Visit 9).

  2. Continue usual intake patterns of caffeine- or xanthine-containing products (e.g., coffee, tea, cola drinks, and chocolate) without significant change for the duration of the study.

  3. Abstain from alcohol for at least 24 hours before the start of each MRI and TMS session. Participants who use tobacco products will be informed that use will be allowed only in between intervention sessions.

Exclusion Criteria:

  1. Pregnancy

  2. Primary psychiatric condition other than MDD requiring treatment except stable comorbid anxiety disorder

  3. History of or current psychotic disorder or bipolar disorder

  4. Severe borderline personality disorder.

  5. Diagnosis of Intellectual Disability or Autism Spectrum Disorder

  6. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal

  7. Urine screening test positive for illicit substances

  8. Active suicidal ideation (defined as an MSSI > 8) or a suicide attempt (as defined by the C-SSRS) within the past one year

  9. Any history of ECT (greater than 8 sessions) without meeting responder criteria

  10. Recent (within 4 weeks of any clinical effect) or concurrent use of rapid acting antidepressant agent (i.e., ketamine or a course of ECT)

  11. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma

  12. Untreated or insufficiently treated endocrine disorder.

  13. Contraindication to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion)

  14. Contraindication to MRI (ferromagnetic metal in their body)

  15. Treatment with another investigational drug or other intervention within the study period

  16. Depth-adjusted aiTBS treatment dose > 65% maximum stimulator output (MSO)

  17. Unstable symptoms between screening and baseline as defined by a ≥ 30% change in MADRS-S score.

  18. Any other condition deemed by the PD to interfere with the study or increase risk to the participant

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine Stanford California United States 94305

Sponsors and Collaborators

  • Stanford University

Investigators

  • Study Director: Nolan Williams, MD, Stanford University
  • Principal Investigator: David Spiegel, MD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
David Spiegel, Professor, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford University
ClinicalTrials.gov Identifier:
NCT04243798
Other Study ID Numbers:
  • 54909
First Posted:
Jan 28, 2020
Last Update Posted:
May 6, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by David Spiegel, Professor, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford University
transcranial magnetic stimulation
theta burst
Additional relevant MeSH terms:
Depression
Depressive Disorder, Treatment-Resistant

Study Results

No Results Posted as of May 6, 2022